trending Market Intelligence /marketintelligence/en/news-insights/trending/b6-ujx4lpyrs0shs0jpzww2 content esgSubNav
In This List

Acasti Pharma raises $19.1M via offering of common stock in US

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Acasti Pharma raises $19.1M via offering of common stock in US

Acasti Pharma Inc. closed its underwritten public offering of 16.6 million common shares in the U.S. with gross proceeds of about US$19.1 million.

The Laval, Quebec-based pharmaceutical company said underwriters fully exercised their overallotment option to buy an additional 2,490,000 common shares.

Shares in the offering were priced at US$1 apiece.

Acasti Pharma will use the proceeds to fund its late-stage cardiovascular drug trial, named Trilogy, to advance partnering discussions and for working capital and general corporate purposes.

The phase 3 study is evaluating the safety and effectiveness of the experimental drug CaPre to treat severe hypertriglyceridemia, a chronic metabolic condition that heightens the risk of pancreatic and heart diseases.

Oppenheimer & Co. Inc. acted as sole book-running manager for the offering, with Aegis Capital Corp. as co-manager.

Acasti Pharma said its concurrent public offering in Canada of C$24 million of common shares at C$1.28 apiece is expected to close on Oct. 22. Underwriters will have an overallotment option to buy up to an additional 15% of the shares offered.